Jan 03, 2017 12:31 pm UTC| Business
CARMIEL, Israel, Jan. 03, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of...
Jan 03, 2017 12:31 pm UTC| Business
CARMIEL, Israel, Jan. 03, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company’s phase II clinical trial of alidornase alfa for the treatment of...
Delek US Holdings to Acquire Remaining Outstanding Shares of Alon USA
Jan 03, 2017 12:31 pm UTC| Business
Combination creates a Permian focused company with refining, logistics, retail and marketing operations with a combined enterprise value of approximately $2.8 billionAll-stock transaction at a fixed exchange ratio of...
Delek US Holdings to Acquire Remaining Outstanding Shares of Alon USA
Jan 03, 2017 12:31 pm UTC| Business
Combination creates a Permian focused company with refining, logistics, retail and marketing operations with a combined enterprise value of approximately $2.8 billionAll-stock transaction at a fixed exchange ratio of...
Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc
Jan 03, 2017 12:31 pm UTC| Business
DUBLIN, Ireland, Jan. 03, 2017 -- Flamel Technologies SA, completed its previously announced cross-border merger with and into its wholly-owned Irish subsidiary, Avadel Pharmaceuticals plc (NASDAQ:AVDL) (Avadel),...
Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc
Jan 03, 2017 12:31 pm UTC| Business
DUBLIN, Ireland, Jan. 03, 2017 -- Flamel Technologies SA, completed its previously announced cross-border merger with and into its wholly-owned Irish subsidiary, Avadel Pharmaceuticals plc (NASDAQ:AVDL) (Avadel),...
Otonomy to Present at the J.P. Morgan Healthcare Conference
Jan 03, 2017 12:30 pm UTC| Business
SAN DIEGO, Jan. 03, 2017 -- Otonomy, Inc.(NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that...